Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials

doi:10.4292/wjgpt.120377

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(11)

(12)

(0)

(194)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Sep 5, 2026; 17(3): 120377
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120377

Table 2 Overall survival estimates of first line treatments for advanced hepatocellular carcinoma compared to sorafenib and to camrelizumab plus rivoceranib are reported as restricted mean survival time (expressed in months) with 95%CI in the overall population at 28 months of follow-up

Arm	RMST (months)	Lower 95%CI	Upper 95%CI	Difference in RMST compared to sorafenib/lenvatinib (months)	Difference in RMST compared to camrelizumab + rivoceranib (months)
Sorafenib (pooled)	15.87	15.33	16.40	0	-3.78
Camrelizumab + rivoceranib	19.65	18.42	20.87	3.78	0
Tremelimumab + durvalumab	17.18	16.17	18.20	1.32	-2.46
Atezolizumab + bevacizumab	18.22	17.11	19.32	2.35	-1.42
Toripalimab + bevacizumab	16.88	15.93	17.82	1.01	-2.77
Anlotinib + penpulimab	17.94	16.37	19.51	2.07	-1.71
Lenvatinib (pooled)	18.86	18.21	19.58	3.01	-0.77
Pembrolizumab + lenvatinib	19.63	18.73	20.54	3.77	-0.01
Nivolumab + ipilimumab	19.14	18.03	20.24	3.27	-0.51

RMST: Restricted mean survival time.

Full Size Table

Citation: Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; 17(3): 120377
URL: https://www.wjgnet.com/2150-5349/full/v17/i3/120377.htm
DOI: https://dx.doi.org/10.4292/wjgpt.120377

Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; 17(3): 120377 [PMID: 42707851 DOI: 10.4292/wjgpt.120377]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.